TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:52
Evaxion Biotech A/S ( EVAX ) https://www.evaxion-biotech.com
0.69USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Denmark
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-60.18%
EVAX
SPY
30.72%
EVAX
0.00%
SPY
112.82%
EVAX
0.00%
SPY
201.04%
EVAX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
17.86
21.70
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.71
0.00
7.05
-6.84
0.00
-0.90
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
173.53
175.40
0.00
Other Earnings and Cash Flow Stats:
Evaxion Biotech A/S ( EVAX ) Net Income TTM ($MM) is -23.06
Evaxion Biotech A/S ( EVAX ) Operating Income TTM ($MM) is -24.54
Evaxion Biotech A/S ( EVAX ) Owners' Earnings Annual ($MM) is 0.00
Evaxion Biotech A/S ( EVAX ) Current Price to Owners' Earnings ratio is 0.00
Evaxion Biotech A/S ( EVAX ) EBITDA TTM ($MM) is -22.19
Evaxion Biotech A/S ( EVAX ) EBITDA Margin is 0.00%
Capital Allocation:
Evaxion Biotech A/S ( EVAX ) has paid 0.00 dividends per share and bought back -3.228211 million shares in the past 12 months
Evaxion Biotech A/S ( EVAX ) has increased its debt by 0.835 million USD in the last 12 months
Capital Structure:
Evaxion Biotech A/S ( EVAX ) Interest-bearing Debt ($MM) as of last quarter is 10
Evaxion Biotech A/S ( EVAX ) Annual Working Capital Investments ($MM) are 4
Evaxion Biotech A/S ( EVAX ) Book Value ($MM) as of last quarter is 2
Evaxion Biotech A/S ( EVAX ) Debt/Capital as of last quarter is 432%
Other Balance Sheet Stats:
Evaxion Biotech A/S ( EVAX ) has 7 million in cash on hand as of last quarter
Evaxion Biotech A/S ( EVAX ) has 4 million of liabilities due within 12 months, and long term debt 8 as of last quarter
Evaxion Biotech A/S ( EVAX ) has 27 common shares outstanding as of last quarter
Evaxion Biotech A/S ( EVAX ) has 0 million USD of preferred stock value
Academic Scores:
Evaxion Biotech A/S ( EVAX ) Altman Z-Score is -10.57 as of last quarter
Evaxion Biotech A/S ( EVAX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Evaxion Biotech A/S ( EVAX ) largest shareholder is TWO SIGMA SECURITIES, LLC owning 15188 shares at 0.01 ($MM) value
(an insider) shares of Evaxion Biotech A/S ( EVAX ) for the amount of $ on
31.31% of Evaxion Biotech A/S ( EVAX ) is held by insiders, and 0.63% is held by institutions
Evaxion Biotech A/S ( EVAX ) went public on 2021-02-05
Other Evaxion Biotech A/S ( EVAX ) financial metrics:
FCF:-1.86
Unlevered Free Cash Flow:0.00
EPS:-0.84
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-896.73
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Evaxion Biotech A/S ( EVAX ) :
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.